Retatrutide

Retatrutide is an investigational weight-loss and diabetes drug from Eli Lilly, notable for being a triple agonist: it activates three receptors at once — GLP-1, GIP, and glucagon. If semaglutide hits one target and tirzepatide hits two, retatrutide is the next step in that progression.

Why it’s generating buzz

Early- and mid-stage trial results have been striking — a Phase 2 trial reported average weight loss around 24% at 48 weeks on the highest dose, with the curve not clearly plateauing yet, which is what set expectations high. Adding glucagon-receptor activity is thought to increase energy expenditure on top of the appetite effects, a somewhat different mechanism from the drugs already on the market.

The essential caveat

Retatrutide is not approved and not available by prescription. As of now it remains in clinical trials, with larger Phase 3 studies underway to confirm safety and effectiveness. Early results are exactly that — early — and impressive Phase 2 numbers don’t always survive larger, longer trials. Side-effect and long-term safety data are still being gathered.

What it means for you today

Practically: nothing yet, except as context. It’s a sign of how fast this field is moving, and a reasonable thing to ask your prescriber about someday — but the drugs to make decisions about now are the approved ones. Treat retatrutide as a “watch this space” entry, and be skeptical of anyone selling “retatrutide” outside a clinical trial, since an unapproved compound from an unregulated source is a real safety risk.